PFE - Vaxart Has 3 Advantages Over Pfizer and Moderna
Things were looking gloomy for Vaxart (NASDAQ: VXRT) a few months ago. The clinical-stage biotech company reported that its COVID-19 vaccine candidate didn't produce neutralizing antibodies in a phase 1 trial. These antibodies are considered key since their role is to fight infection. As a result, Vaxart's shares tumbled 58% in one trading session.
But all is not lost. This week, the company shared details of its studies and its development plans. Vaxart's investigational vaccine works in a different manner than those of market leaders Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) . And it may even offer some advantages. Let's look at three of them.
Image source: Getty Images.
For further details see:
Vaxart Has 3 Advantages Over Pfizer and Moderna